Insider Trading Alert - CRZO, ARTC, MDCO, ED And LNG Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Feb. 5, 2014, 146 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $51.84 to $26,546,700.00.

Highlighted Stocks Traded by Insiders:

Carrizo Oil & Gas (CRZO) - FREE Research Report

Johnson S P Iv who is President and CEO at Carrizo Oil & Gas sold 6,000 shares at $40.53 on Feb. 5, 2014. Following this transaction, the President and CEO owned 632,837 shares meaning that the stake was reduced by 0.94% with the 6,000-share transaction.

The shares most recently traded at $40.31, down $0.22, or 0.54% since the insider transaction. Historical insider transactions for Carrizo Oil & Gas go as follows:

  • 4-Week # shares sold: 10,000
  • 12-Week # shares sold: 54,229
  • 24-Week # shares sold: 102,229

The average volume for Carrizo Oil & Gas has been 1.2 million shares per day over the past 30 days. Carrizo Oil & Gas has a market cap of $1.9 billion and is part of the basic materials sector and energy industry. Shares are down 9.02% year-to-date as of the close of trading on Wednesday.

Carrizo Oil & Gas, Inc., an independent energy company, engages in the exploration, development, and production of oil and gas primarily in the United States. The company has a P/E ratio of 20.4. Currently there are 9 analysts that rate Carrizo Oil & Gas a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CRZO - FREE

TheStreet Quant Ratings rates Carrizo Oil & Gas as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, impressive record of earnings per share growth, compelling growth in net income, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Carrizo Oil & Gas Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

ArthroCare Corporation (ARTC) - FREE Research Report

Prothro Bruce who is Chief Regulatory Officer & SVP at ArthroCare Corporation sold 3,474 shares at $48.59 on Feb. 5, 2014. Following this transaction, the Chief Regulatory Officer & SVP owned 35,947 shares meaning that the stake was reduced by 8.81% with the 3,474-share transaction.

The shares most recently traded at $49.80, up $1.21, or 2.43% since the insider transaction. Historical insider transactions for ArthroCare Corporation go as follows:

  • 4-Week # shares sold: 5,682
  • 12-Week # shares sold: 11,682
  • 24-Week # shares sold: 15,524

The average volume for ArthroCare Corporation has been 317,700 shares per day over the past 30 days. ArthroCare Corporation has a market cap of $1.4 billion and is part of the health care sector and health services industry. Shares are up 22.37% year-to-date as of the close of trading on Wednesday.

ArthroCare Corporation, medical device company, engages in the development, manufacture, and marketing of surgical products based on its Coblation technology in the Americas and internationally. The company has a P/E ratio of 78.2. Currently there are 4 analysts that rate ArthroCare Corporation a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on ARTC - FREE

TheStreet Quant Ratings rates ArthroCare Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in net income, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full ArthroCare Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Medicines (MDCO) - FREE Research Report

Meanwell Clive who is Chairman & CEO at Medicines sold 10,000 shares at $34.29 on Feb. 5, 2014. Following this transaction, the Chairman & CEO owned 287,773 shares meaning that the stake was reduced by 3.36% with the 10,000-share transaction.

The shares most recently traded at $33.22, down $1.07, or 3.23% since the insider transaction. Historical insider transactions for Medicines go as follows:

  • 4-Week # shares sold: 383
  • 12-Week # shares sold: 51,650
  • 24-Week # shares sold: 68,118

The average volume for Medicines has been 714,600 shares per day over the past 30 days. Medicines has a market cap of $2.1 billion and is part of the health care sector and drugs industry. Shares are down 14.45% year-to-date as of the close of trading on Wednesday.

The Medicines Company provides medical solutions for patients in acute and intensive care hospitals worldwide. The company has a P/E ratio of 53.2. Currently there are 5 analysts that rate Medicines a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on MDCO - FREE

TheStreet Quant Ratings rates Medicines as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had somewhat weak growth in earnings per share. Get the full Medicines Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Consolidated Edison (ED) - FREE Research Report

Hoglund Robert N who is Svp & Cfo at Consolidated Edison bought 43 shares at $53.72 on Feb. 5, 2014. Following this transaction, the Svp & Cfo owned 35,467 shares meaning that the stake was reduced by 0.12% with the 43-share transaction.

Oates Joseph P who is SVP, Business Shared Services at Consolidated Edison bought 10 shares at $53.72 on Feb. 5, 2014. Following this transaction, the SVP, Business Shared Services owned 20,542 shares meaning that the stake was reduced by 0.05% with the 10-share transaction.

Ivey Craig S who is President (CECONY) at Consolidated Edison bought 110 shares at $54.39 on Feb. 5, 2014. Following this transaction, the President (CECONY) owned 37,712 shares meaning that the stake was reduced by 0.29% with the 110-share transaction.

Nadkarni Gurudatta D who is VP, Strategic Planning at Consolidated Edison bought 39 shares at $53.72 on Feb. 5, 2014. Following this transaction, the VP, Strategic Planning owned 3,844 shares meaning that the stake was reduced by 1.02% with the 39-share transaction.

Moore Elizabeth D who is SVP & General Counsel at Consolidated Edison bought 41 shares at $53.72 on Feb. 5, 2014. Following this transaction, the SVP & General Counsel owned 17,103 shares meaning that the stake was reduced by 0.24% with the 41-share transaction.

Muccilo Robert who is VP & Chief Accounting Officer at Consolidated Edison bought 37 shares at $53.72 on Feb. 5, 2014. Following this transaction, the VP & Chief Accounting Officer owned 3,922 shares meaning that the stake was reduced by 0.96% with the 37-share transaction.

McAvoy John who is President & CEO at Consolidated Edison bought 83 shares at $53.72 on Feb. 5, 2014. Following this transaction, the President & CEO owned 11,081 shares meaning that the stake was reduced by 0.75% with the 83-share transaction.

Cawley Timothy who is President & CEO, O&R at Consolidated Edison bought 43 shares at $53.72 on Feb. 5, 2014. Following this transaction, the President & CEO, O&R owned 535 shares meaning that the stake was reduced by 8.76% with the 43-share transaction.

The shares most recently traded at $53.56, down $0.16, or 0.3% since the insider transaction. Historical insider transactions for Consolidated Edison go as follows:

  • 4-Week # shares bought: 580
  • 12-Week # shares bought: 856
  • 12-Week # shares sold: 3,100
  • 24-Week # shares bought: 1,769
  • 24-Week # shares sold: 3,100

The average volume for Consolidated Edison has been 2.0 million shares per day over the past 30 days. Consolidated Edison has a market cap of $15.7 billion and is part of the utilities sector and utilities industry. Shares are down 3.42% year-to-date as of the close of trading on Wednesday.

Consolidated Edison, Inc., through its subsidiaries, engages in regulated electric, gas, and steam delivery businesses. The stock currently has a dividend yield of 4.7%. The company has a P/E ratio of 15.3. Currently there are no analysts that rate Consolidated Edison a buy, 2 analysts rate it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ED - FREE

TheStreet Quant Ratings rates Consolidated Edison as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, attractive valuation levels, growth in earnings per share and increase in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Consolidated Edison Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Cheniere Energy (LNG) - FREE Research Report

Souki Charif who is Chairman, CEO & President at Cheniere Energy sold 30,000 shares at $43.50 on Feb. 5, 2014. Following this transaction, the Chairman, CEO & President owned 6.4 million shares meaning that the stake was reduced by 0.47% with the 30,000-share transaction.

The shares most recently traded at $40.96, down $2.54, or 6.21% since the insider transaction. Historical insider transactions for Cheniere Energy go as follows:

  • 4-Week # shares sold: 32,000
  • 12-Week # shares sold: 807,150
  • 24-Week # shares sold: 1.0 million

The average volume for Cheniere Energy has been 3.6 million shares per day over the past 30 days. Cheniere Energy has a market cap of $10.2 billion and is part of the basic materials sector and energy industry. Shares are down 0.88% year-to-date as of the close of trading on Wednesday.

Cheniere Energy, Inc., an energy company, engages in the liquefied natural gas (LNG) related business. It operates through two segments, LNG Terminal Business, and LNG and Natural Gas Marketing Business. Currently there are 4 analysts that rate Cheniere Energy a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on LNG - FREE

TheStreet Quant Ratings rates Cheniere Energy as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance and growth in earnings per share. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and generally higher debt management risk. Get the full Cheniere Energy Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Data for this article provided by Zacks Investment Research

null

More from Markets

Boeing Is Back to Cruising Altitude; GM Gets Assist From Amazon -- ICYMI

Boeing Is Back to Cruising Altitude; GM Gets Assist From Amazon -- ICYMI

Investors Shouldn't Be Worried About Trump's Trade Tariffs: Ian Bremmer

Investors Shouldn't Be Worried About Trump's Trade Tariffs: Ian Bremmer

Aceto's Search for Deal May Be Slowed by DOJ Subpoena

Aceto's Search for Deal May Be Slowed by DOJ Subpoena

Dow and S&P 500 Finish Higher Amid Strong Corporate Earnings

Dow and S&P 500 Finish Higher Amid Strong Corporate Earnings

Veteran Foreign Affairs Expert Ian Bremmer Reveals How to Price Political Risk

Veteran Foreign Affairs Expert Ian Bremmer Reveals How to Price Political Risk